Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DVS SR in Pain Associated with Diabetic Peripheral Neuropathy
NCT00283842Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Mar 2006
- Primary completion
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of desvenlafaxine in diabetic peripheral neuropathy (DPN) (5 arms), sponsored by Pfizer. Primary endpoint: Change in Mean Pain Severity Score From Baseline at 13 weeks. Started Mar 2006; status: terminated.
02
Drugs
desvenlafaxine
03
Conditions
diabetic peripheral neuropathy (DPN)
Beyond the preview
Go deeper on NCT00283842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00283842.